News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
12,990 Results
Type
Article (337)
Company Profile (4)
Press Release (12649)
Section
Business (3733)
Career Advice (3)
Deals (682)
Drug Delivery (1)
Drug Development (1755)
FDA (437)
Job Trends (154)
News (6660)
Policy (585)
Tag
Academia (29)
Alliances (805)
ALS (1)
Alzheimer's disease (4)
Antibody-drug conjugate (ADC) (8)
Approvals (467)
Artificial intelligence (3)
Autoimmune disease (1)
Automation (1)
Bankruptcy (8)
Best Places to Work (128)
Biosimilars (14)
Biotechnology (2)
Bladder cancer (5)
Breast cancer (9)
Cancer (43)
Career advice (3)
Cell therapy (4)
Cervical cancer (3)
Clinical research (1667)
Collaboration (32)
Compensation (62)
Complete response letters (2)
COVID-19 (18)
C-suite (23)
Cystic fibrosis (1)
Data (119)
Diabetes (11)
Diagnostics (31)
Digital health (2)
Drug pricing (1)
Duchenne muscular dystrophy (2)
Earnings (1743)
Events (2050)
Executive appointments (30)
FDA (528)
Funding (25)
Gene therapy (22)
GLP-1 (3)
Government (38)
Guidances (9)
Healthcare (286)
Immunology and inflammation (2)
Indications (1)
Infectious disease (18)
Intellectual property (2)
Interviews (1)
IPO (291)
Job creations (28)
Job search strategy (3)
Layoffs (6)
Legal (112)
Lung cancer (6)
Lymphoma (6)
Machine learning (2)
Manufacturing (11)
Medical device (358)
Medtech (358)
Mergers & acquisitions (418)
Metabolic disorders (12)
Multiple sclerosis (6)
Neurodegenerative disease (2)
Neuroscience (16)
NextGen: Class of 2026 (111)
Non-profit (42)
Opinion (1)
Ovarian cancer (4)
Pain (17)
Parkinson's disease (2)
Patents (3)
Patient recruitment (17)
People (1241)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase 1 (340)
Phase 2 (797)
Phase 3 (696)
Pipeline (126)
Postmarket research (35)
Preclinical (112)
Radiopharmaceuticals (1)
Rare diseases (9)
Real estate (42)
Regulatory (538)
Research institute (17)
Series A (3)
Series B (7)
Spinal muscular atrophy (1)
Startups (65)
Supply chain (1)
Vaccines (4)
Venture capital (1)
Date
Today (3)
Last 7 days (10)
Last 30 days (46)
Last 365 days (714)
2026 (68)
2025 (731)
2024 (826)
2023 (959)
2022 (1302)
2021 (1289)
2020 (978)
2019 (706)
2018 (584)
2017 (682)
2016 (619)
2015 (771)
2014 (499)
2013 (405)
2012 (369)
2011 (339)
2010 (317)
Location
Africa (7)
Alabama (2)
Arizona (3)
Asia (866)
Australia (118)
California (292)
Canada (69)
China (18)
Colorado (1)
Connecticut (5)
Delaware (5)
Europe (1541)
Florida (20)
Georgia (35)
Idaho (1)
Illinois (14)
India (2)
Indiana (3)
Japan (15)
Kansas (1)
Maryland (16)
Massachusetts (213)
Michigan (21)
Minnesota (7)
New Jersey (102)
New York (64)
North Carolina (62)
Northern California (117)
Ohio (55)
Pennsylvania (29)
Rhode Island (2)
South America (11)
South Carolina (2)
Southern California (127)
Tennessee (20)
Texas (8)
United States (996)
Utah (2)
Washington State (25)
Wisconsin (1)
12,990 Results for "azura ophthalmics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
March 28, 2024
·
9 min read
Drug Development
Azura Ophthalmics Announces Enrollment of First Patient in Phase 3 Clinical Trial for AZR-MD-001 in Patients with Meibomian Gland Dysfunction (MGD)
Azura Ophthalmics Ltd. today announced that the first patient has been enrolled in the ASTRO study – a Phase 3 clinical trial assessing the efficacy and safety of AZR-MD-001 in patients with clinical signs and symptoms of Meibomian Gland Dysfunction (MGD).
June 4, 2024
·
6 min read
Drug Development
Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort
Azura Ophthalmics Ltd. today announced positive topline efficacy and safety results from a Phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of Meibomian Gland Dysfunction (MGD).
December 18, 2023
·
10 min read
Press Releases
ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization
February 3, 2026
·
5 min read
Business
Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Azura Ophthalmics Ltd. , a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the formation of its scientific advisory board (SAB).
September 21, 2022
·
8 min read
Azura Ophthalmics Announces Participation at Upcoming Investor Conferences
Azura Ophthalmics Ltd. today announced that members of management will present at BTIG’s Ophthalmology Day 2022, being held on November 29, and at the Piper Sandler 34th Annual Healthcare Conference, being held from November 29 through December 1.
November 21, 2022
·
3 min read
Azura Ophthalmics Announces Participation at the 2023 SVB Securities Global Biopharma Conference
Azura Ophthalmics Ltd. announced that its executive team will hold 1x1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2.
January 17, 2023
·
3 min read
Press Releases
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
January 29, 2026
·
3 min read
Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office.
October 19, 2022
·
5 min read
Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Society of Cataract and Refractive Surgery and Association for Research in Vision and Ophthalmology Annual Meetings
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations featuring positive efficacy and safety data from a Phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
April 20, 2023
·
5 min read
1 of 1,299
Next
